Clinical Trial News and Research

RSS

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today the publication of results from preclinical studies demonstrating that human Serum Amyloid P (hSAP) potently inhibited fibrosis in two independent model systems of kidney fibrosis.

5 Nov 2009

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Raptor Pharmaceutical Corp., today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

5 Nov 2009

Patient enrollment in three late-stage clinical trials completed

Inspire Pharmaceuticals, Inc. announced today patient enrollment is complete in three of its late-stage clinical trials.

5 Nov 2009

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.

5 Nov 2009

Echo Therapeutics commences its Symphony Transdermal Continuous Glucose Monitoring System clinical study

Echo Therapeutics, Inc., a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery announced today that it has initiated a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System (tCGM System) in patients with Type 1 and Type 2 diabetes.

5 Nov 2009

Combination therapy before prostate removal may prevent recurrence of cancer

Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival.

4 Nov 2009

GSK's malaria vaccine trial containing Antigenics’ Stimulon adjuvant enrolls more than 5,000 children

Antigenics, Inc. today indicated that GlaxoSmithKline’s (GSK) Phase III malaria vaccine clinical trial, containing Antigenics’ QS-21 Stimulon® adjuvant, has enrolled more than 5,000 children to date and is expected to involve up to 16,000 children. The pivotal efficacy study of RTS,S, the world’s most clinically advanced malaria vaccine, is ongoing in seven African countries.

4 Nov 2009

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA.

4 Nov 2009

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009 compared to a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2008.

4 Nov 2009

Third quarter 2009 financial results announced by Synta Pharmaceuticals

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended September 30, 2009.

4 Nov 2009

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

CPEX Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2009. For the quarter CPEX reported revenues of $5.0 million and a net loss of $872,000.

4 Nov 2009

BioClinica releases financial results for the third quarter of 2009

BioClinica™, Inc., a global provider of clinical trial services, today announced its financial results for the quarter and nine months ended September 30, 2009. The operating results of Phoenix Data Systems (“PDS”) are included in the financial results following the acquisition of PDS that was completed March 24, 2008.

From Clario 4 Nov 2009

FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial

NovaRx Corporation announced today that the Company has successfully negotiated and received FDA approval for a Special Protocol Assessment (SPA) Protocol Amendment to the pivotal Lucanix® Phase III clinical trial in patients with Non-Small Cell Lung Cancer (NSCLC).

4 Nov 2009

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

All approved therapy regimens to treat patients with hepatitis C are based on interferon, which must be injected. In this clinical trial to be presented at the annual meeting of the American Association for the Study of Liver Diseases, researchers treated patients - both treatment naive and experienced patients - with a twice daily oral combination therapy of a nucleoside polymerase and protease inhibitor.

4 Nov 2009

Phase Forward and PharmaNet Development Group sign multi-year agreement

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year agreement with PharmaNet Development Group, Inc., a global drug development services company, that enables PharmaNet to offer Phase Forward’s InForm™ electronic data capture (EDC) solution to PharmaNet customers worldwide.

4 Nov 2009

Predictive Biosciences commences clinical trials of its bladder cancer assay

Predictive Biosciences Inc. today announced the publication of pilot study results in the November issue of the Journal of Urology, highlighting the Company’s novel urinary biomarker approach to bladder cancer detection that achieves exceptionally high Negative and Positive Predictive Values (NPV and PPV).

4 Nov 2009

LIFE Biosystems to support UT Southwestern's Clinical Trials Management System deployment

LIFE Biosystems AG announced today that it has entered into a master agreement with The University of Texas Southwestern Medical Center at Dallas to provide clinical research consulting services in the area of Clinical Trials Management System (CTMS) deployment support. Financial terms of the agreement were not disclosed.

4 Nov 2009

MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent glioblastoma.

4 Nov 2009

New strategy to eliminate and eradicate malaria unveiled

Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria

4 Nov 2009

XanGo Juice lowers levels of C-reactive protein in overweight and obese people

A new study published in Nutrition Journal indicates that XanGo- Juice, a market-leading, premium mangosteen beverage, has lowered levels of C-reactive protein (CRP) in overweight and obese people in a randomized, double-blind, placebo-controlled human trial.

4 Nov 2009

Clinical Trial News and Research

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Patient enrollment in three late-stage clinical trials completed

USPTO awards Peregrine Pharmaceuticals patent for anti-viral uses of phosphatidylserine targeting antibodies

Echo Therapeutics commences its Symphony Transdermal Continuous Glucose Monitoring System clinical study

Combination therapy before prostate removal may prevent recurrence of cancer

GSK's malaria vaccine trial containing Antigenics’ Stimulon adjuvant enrolls more than 5,000 children

Medivir presents OPERA-1 Phase IIa trial data at the AASLD meeting

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

Third quarter 2009 financial results announced by Synta Pharmaceuticals

CPEX Pharmaceuticals announces third-quarter results; reports net loss of $872,000

BioClinica releases financial results for the third quarter of 2009

FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

Phase Forward and PharmaNet Development Group sign multi-year agreement

Predictive Biosciences commences clinical trials of its bladder cancer assay

LIFE Biosystems to support UT Southwestern's Clinical Trials Management System deployment

MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

New strategy to eliminate and eradicate malaria unveiled

XanGo Juice lowers levels of C-reactive protein in overweight and obese people

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News